跳至主要内容
临床试验/NCT03021161
NCT03021161Unknown4 期

The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers: A Randomized Controlled Trial.

University of Sao Paulo1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2017年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
200
试验地点
1
主要终点
detection the reduction of sensitization in workers exposed to laboratory animal

研究概览

简要总结

This project will be test the effect of probiotics on occupational allergic sensitization, respiratory symptoms and bronchial hyperresponsiveness in workers or students that develop respiratory symptoms exposed to laboratory animals, i.e., small rodents.

详细描述

INTRODUCTION: The objective of the present project is to test the effect of probiotics on occupational allergic sensitization, respiratory symptoms and bronchial hyperresponsiveness in workers or students exposed to laboratory animals, i.e., small rodents.

Furthermore, our study aims to determine changes in immunological patterns with the use of probiotics in adulthood, which could prevent allergic sensitization and allergic diseases.

Probiotics have been used as treatment in various allergic diseases, especially as prevention of child atopic dermatitis by using them during pregnancy, or for neonates and infants.

STUDY DESIGN AND METHODS: This will be a randomized controlled trial involving laboratory animal workers and students exposed to rats, mice, hamsters, guinea pigs or rabbits. Subjects will be recruited in the laboratories of the University of S. Paulo and State University of Campinas (Unicamp). Exposed subjects will be randomly allocated to two groups: treatment and placebo. Both groups will be followed up for two years. Subjects will be evaluated at baseline, after one year and after two years.

Treatment: the intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 and the control group will receive once daily similar capsules containing placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 18 years, both sexes, ability to read, understand and to decide on protocol consenting.
  • Participants should be healthy
  • Animal handling for research purposes as part of regular activities as a worker or student.
  • Planning to continue this activity for the next 2 years.

排除标准

  • Previous laboratory animal handling for 15 days or longer. This exposure may have sensitized or selected people that are not susceptible to sensitizations.
  • Sensitization to any laboratory animal (rat, mouse, hamster, guinea pig or rabbit).
  • Allergic diseases that interfere with the evaluation of study variables.
  • Using immunosuppressive drugs (ex: methotrexate, cyclosporine, leflunomide) or corticosteroids in immunosuppressive doses (e.g.: prednisone doses of 1.0 mg/kg/day or more).
  • Cancer or treatment of neoplasia.
  • Having diseases that cause immunosuppression such as diabetes, AIDS, renal failure, heart failure or other organ failure.
  • Pregnancy, breastfeeding, or not willing to take necessary precautions to avoid a pregnancy during the study.
  • Use of other probiotic products during the study.

研究组 & 干预措施

intervention group

Experimental

The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).

干预措施: Probiotic Formula (Drug)

Placebo Oral Capsule

Placebo Comparator

The control group will receive once daily similar capsules containing placebo.

干预措施: Placebo Oral Capsule (Other)

结局指标

主要结局

detection the reduction of sensitization in workers exposed to laboratory animal

时间窗: two years

To compare the effect of the oral administration of probiotics on the development of occupational sensitization to the effect of a placebo. Sensitization will be assessed by prick test and specific IgE.

次要结局

  • Assessment of symptoms(two years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elcio Vianna

Principal Investigator

University of Sao Paulo

研究点 (1)

Loading locations...

相似试验